Mechanisms of Xiong-Pi-Fang in treating coronary heart disease associated with depression: A systematic pharmacology strategy and in vivo pharmacological validation.

Abstract

BACKGROUND:

Coronary heart disease (CHD) and depression are very common and often co-existing disorders. Xiong-Pi-Fang (XPF), a therapeutic classical traditional Chinese medicine (TCM) formula, has shown satisfactory efficacy in treating CHD associated with depression. However, its mechanism of action is still unknown.

PURPOSE:

To employ a systematic pharmacology approach for identifying the action mechanisms of XPF in treating CHD associated with depression.

METHODS:

We used a systematic pharmacology approach to identify the potential active mechanisms of XPF in treating CHD with depression. Potential active compounds in XPF and the diseases targets were screened using relevant databases to build corresponding pathways, following the experiments that were conducted to confirm whether the presumptive results of systemic pharmacology were correct.

RESULTS:

Network pharmacology predicted 42 key targets and 20 signaling pathways involved in XPF-mediated treatment, with IL-6/JAK2/STAT3/HIF-1α/VEGF-A pathway significantly affected. The common influences were hypothalamic-pituitary-adrenal axis (HPA axis) and glucocorticoid signaling, validated through chronic unexpected mild stress (CUMS) with isoprenaline (ISO) for inducing CHD within the depression model in rats. In addition, XPF intake reduced depressive-like behaviors and improved ECG ischemic changes. Furthermore, XPF exerted some anti-inflammatory effects by inhibiting the interleukin-6 (IL-6) induced phosphorylation of janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3), ultimately downregulating hypoxia-inducible factor 1-α (HIF-1α) and vascular endothelial growth factor-A (VEGF-A) activation. The dysfunctional HPA axis feedback loop was also regulated, which enhanced the glucocorticoid receptor (GR) expression. In contrast, it improved glucocorticoid resistance by reducing the mineralocorticoid receptor expression.

CONCLUSIONS:

Suppressing IL-6 release and maintaining the HPA feedback loop balance could be the primary mechanism of XPF against CHD with depression. The significance of the IL-6 and HPA axis identified indicates their potential as essential targets for CHD therapy with depression.

• Authors: Fangjuan Deng, Xiaofeng Li, Cheng Tang, Jinhong Chen, Boya Fan, Jiayu Liang, Xin Zhen, Rui Tao, Shaoqiang Zhang, Zidong Cong, Wuxun Du, Hucheng Zhao, Liang Xu
• Journal: Journal of ethnopharmacology (J Ethnopharmacol) Vol. 298 Pg. 115631 (Nov 15 2022) ISSN: 1872-7573 [Electronic] Ireland
• PMID: 35987411 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Elsevier B.V. All rights reserved.

Chemical References

• Drugs, Chinese Herbal
• Interleukin-6
• Vascular Endothelial Growth Factor A

Topics

• Animals
• Coronary Disease (drug therapy, metabolism)
• Depression (drug therapy, metabolism)
• Drugs, Chinese Herbal (metabolism, pharmacology, therapeutic use)
• Hypothalamo-Hypophyseal System
• Interleukin-6 (metabolism)
• Network Pharmacology
• Pituitary-Adrenal System
• Rats
• Vascular Endothelial Growth Factor A (metabolism)